Published on
June 17, 2021

The Good Shroom Co Receives Authorization To Commence Sales Of The Velada Cannabis And Functional Mushroom Product Line

Montreal (Quebec) Canada, June 17, 2021 – The Good Shroom Co Inc. (the “Company” or “TGSC”) (TSXV: MUSH), is pleased to announce that its wholly owned subsidiary, Teonan Biomedical Inc. (“Teonan”), has received authorization from Health Canada to commence the sale and the distribution of its beverages which are Canada’s first cannabis infused beverage line made with functional mushroom extracts.

Teonan holds a micro-processing license delivered by Health Canada under the Cannabis Act, which allows it to manufacture and develop topicals, extracts and edible cannabis products which includes beverages. Before sales of the Velada beverages could commence, Teonan was required to demonstrate its finished products and quality control procedures complied with Health Canada’s strict guidelines. Teonan’s micro-processing license was amended by Health Canada allowing it to distribute the Velada products nationwide, through various provincial retailers, including the Société Quebecoise du Cannabis (SQDC) which is Canada’s largest provincial cannabis retailer. A micro-processing license has an annual cannabis extract processing limit of 150,000,000 mg per year. With Health Canada’s limit of 10 mg of THC per unit, this equals up to 15,000,000 units containing THC which can be sold yearly. The Company has strategically chosen a micro-processing license instead of a standard processing license due to the high cannabis processing limit with the reduced cost associated to maintaining this type of license.

Velada is the first mushroom-based instant wellness beverage in Canada which contains cannabinoids. The beverage mixes which come in powdered form are vegan, dairy free, GMO free, gluten free and all contain 100 mg of functional mushroom extracts and a 30 mg dose of CBD per serving. The Company will also be offering a low THC version of the beverages with a 2:1 CBD:THC ratio for optimal effectiveness, with 4.5mg of THC and 9 mg of CBD per serving in order to have an expanded and versatile offering to appeal to a wider variety of customers. Flavours available for distribution include hot chocolate, coffee and golden milk latte. The Company anticipates expanding the Velada product line with additional flavours and products following market response and emerging industry trends. This authorization to begin sales also allows the company to initiate its agreement with its sales broker Velvet Management Inc., Canada’s leading cannabis sales agency, which represents the company across Canada.

“We have been eagerly awaiting this authorization and we are ready to move forward” stated Eric Ronsse, the Chief Executive Officer of TGSC. “With relatively few established beverage suppliers and high barriers to entry, we expect the quality of our product, the variety of the offering and attractive price point, will allow us to capture a share of the market and build a strong and loyal consumer base.”  In Canada the cannabis-infused beverage market is estimated at $529 million per year.

In connection with the receipt of the authorization, the Company will issue 1,000,000 common shares to Mr. Scott Jardin, it’s Chief Financial Officer, as per the terms of a performance share agreement (the “Agreement”) entered into in September 2020. Under the Agreement, Mr. Scott is entitled to receive 1,000,000 common shares upon receipt of all regulatory permits and authorizations required for the commercialization of the Velada products.  Mr. Jardin can earn additional tranches of common shares (maximum of 2,000,000) when the Company reaches targeted sales for the Velada products in the next 12 months. All shares issued pursuant to the Agreement are subject to a hold period until April 15, 2022, in addition to the escrow requirements of policy 5.4 of the TSX Venture Exchange which provides for a release over 36 months starting April 26, 2021 (please see Filing Statement available at for details on the agreement and escrow release schedule).

About the Company

TGSC’s mission is to build clean label brands that are synonymous with functionality, flavour and quality, rooted in a company recognized for having a socially responsible approach. Through its wholly owned subsidiary, Teonan, it manufactures and sells functional beverages under its two brands: Teonan and Velada. Inspired by the relationships ancient cultures held with mushrooms and in line with growing consumer trends towards functional foods, Teonan created the instant beverage lines using a custom blend of organic mushroom extracts chosen for their known health benefits, all the while keeping the focus on developing delicious flavors.”  All of Teonan’s instant beverage mixes are certified organic (Ecocert - USDA), vegan, dairy free, GMO free and gluten free.  Teonan began direct to consumer sales of the Teonan beverages in North America, in December 2019, via its online stores and sales of the Velada beverages to authorized retailers is expected to commence in the coming weeks.   

For additional information:

Teonan Biomedical Inc.

Eric Ronsse, President, tel: (514) 924-2574  | website:


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Information

This press release contains statements which constitute “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Corporation with respect to future business activities and sales. Forward-looking statements are often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions.  Investors are cautioned that forward-looking statements are not based on historical facts but instead reflect the Corporation’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Corporation believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed thereon, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected are the following: expectations with respect to the future growth of wellness beverages and edible cannabis industry; market acceptance of the products, plans for and timing of expansion of its products; expectations regarding competition; maintaining in good standing all necessary regulatory licenses and authorizations for its products; the benefits, safety, efficacy, dosing and social acceptance of cannabis related products and no material changes in the legal environment; changes in applicable laws and regulations both locally and in foreign jurisdictions; compliance with extensive government regulation; operational risks related to and COVID-19 or other pandemic and supply chain disruptions.  Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended and such changes could be material. The Company does not intend, and do not assume any obligation, to update the forward-looking statements except as otherwise required by applicable law.  Trading in the securities of the Company should be considered highly speculative.